Alzamend Total Assets from 2010 to 2024
| ALZN Stock | USD 1.29 0.02 1.53% |
Total Assets | First Reported 2010-12-31 | Previous Quarter 631.6 K | Current Value 600 K | Quarterly Volatility 3.5 M |
Check Alzamend Neuro financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alzamend Neuro's main balance sheet or income statement drivers, such as Interest Expense of 9.6 K, Interest Income of 0.0 or Depreciation And Amortization of 48.2 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Alzamend financial statements analysis is a perfect complement when working with Alzamend Neuro Valuation or Volatility modules.
Alzamend | Total Assets |
Latest Alzamend Neuro's Total Assets Growth Pattern
Below is the plot of the Total Assets of Alzamend Neuro over the last few years. Total assets refers to the total amount of Alzamend Neuro assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Alzamend Neuro books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Alzamend Neuro's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alzamend Neuro's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 631.59 K | 10 Years Trend |
|
Total Assets |
| Timeline |
Alzamend Total Assets Regression Statistics
| Arithmetic Mean | 2,659,902 | |
| Geometric Mean | 1,798,204 | |
| Coefficient Of Variation | 131.93 | |
| Mean Deviation | 2,048,660 | |
| Median | 1,500,917 | |
| Standard Deviation | 3,509,203 | |
| Sample Variance | 12.3T | |
| Range | 13.9M | |
| R-Value | 0.31 | |
| Mean Square Error | 12T | |
| R-Squared | 0.09 | |
| Significance | 0.27 | |
| Slope | 240,980 | |
| Total Sum of Squares | 172.4T |
Alzamend Total Assets History
Other Fundumenentals of Alzamend Neuro
Alzamend Neuro Total Assets component correlations
Click cells to compare fundamentals
About Alzamend Neuro Financial Statements
Alzamend Neuro investors utilize fundamental indicators, such as Total Assets, to predict how Alzamend Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Assets | 631.6 K | 600 K |
Pair Trading with Alzamend Neuro
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alzamend Neuro position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alzamend Neuro will appreciate offsetting losses from the drop in the long position's value.Moving together with Alzamend Stock
| 0.8 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.67 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.7 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Alzamend Stock
| 0.75 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.57 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.46 | MNOV | MediciNova | PairCorr |
| 0.45 | PHVS | Pharvaris BV | PairCorr |
| 0.43 | OPT | Opthea | PairCorr |
The ability to find closely correlated positions to Alzamend Neuro could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alzamend Neuro when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alzamend Neuro - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alzamend Neuro to buy it.
The correlation of Alzamend Neuro is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alzamend Neuro moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alzamend Neuro moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alzamend Neuro can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Alzamend Neuro Correlation against competitors. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (142.87) | Return On Assets (2.14) | Return On Equity (44.08) |
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.